THERAPY DOSSIER · th-2428a654f0ac

Recombinant human HMGB1 (rhHMGB1), with the TLR9 agonist CpG-ODN 1826 tested as a complementary approach

Biologic · No ChEMBL entity for recombinant HMGB1 or for CpG-ODN 1826. CpG-ODN class acts as a TLR9 agonist.

Evidence & regulatory context

Mechanism: No ChEMBL entity for recombinant HMGB1 or for CpG-ODN 1826. CpG-ODN class acts as a TLR9 agonist.
Target: Not recorded
Injury models: Ischaemia-reperfusion
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 5

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00190424 ↗Injury indicationPHASE2completed

Multicentric randomized phase 2: immunotherapy with CpG-ODN in malignant glioblastoma

Glioblastoma

Enrolment: 80 · Results not recorded

NCT06047015 ↗PHASE1/PHASE2not yet recruiting

Immune response to irreversible electroporation (NanoKnife) and a checkpoint inhibitor with or without CpG oligodeoxynucleotides for stage IV colorectal cancer

Liver Metastasis Colon Cancer

Enrolment: 12 · Results not recorded

NCT03410901 ↗PHASE1completed

Intratumoral injection of SD-101, an immunostimulatory CpG (TLR9 agonist), with BMS-986178 and local radiation in low-grade B-cell lymphomas

B-Cell Non-Hodgkin Lymphoma · Follicular Lymphoma · Mantle Cell Lymphoma · Marginal Zone Lymphoma

Enrolment: 14 · Results not recorded

NCT03373214 ↗PHASE1completed

Phase 1 safety and immunogenicity of Na-GST-1/Alhydrogel with or without a CpG ODN adjuvant in Gabonese adults

Hookworm Infection

Enrolment: 24 · Results not recorded

NCT00369291 ↗PHASE1terminated

CPG 7909 oligodeoxynucleotides after autologous transplantation to enhance immune reconstitution

Germ Cell Tumor · Leukemia · Lymphoma · Multiple Myeloma

Enrolment: 19 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31209243 ↗2019Mixed findings

TLR9 is essential for HMGB1-mediated post-myocardial infarction tissue repair through affecting apoptosis, cardiac healing, and angiogenesis

MouseIschaemia-reperfusionCardiacC57BL/6 wild-type and TLR9 knockout on a C57BL/6 backgroundMalen = Not fully reported in the retrieved text; CpG-ODN 1826 grou…Intramyocardial (left ventricular) injection for rhHMGB1; intraperitoneal injection for CpG-ODN 18262.5 ug rhHMGB1 in 100 ul PBS per mouse; CpG-ODN 1826 10 ug…1 h before left anterior descending artery ligation

Model: Permanent proximal left anterior descending coronary artery ligation with 7-0 silk via left hemithoracotomy to induce myocardial infarction, with sham-operated controls undergoing the same procedure without ligation

Intramyocardial rhHMGB1 given 1 h before ligation improved 28-day survival in wild-type mice (79.17% versus 52.17% for PBS-treated wild-type, log-rank p=0.0447), reduced cardiac rupture and infarct size, increased infarct wall thickness and collagen volume fraction, improved cardiac function, raise…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…